17 Feb Borderline ovarian tumours differ from epithelial ovarian cancer by their low .. Gouy S. Cirugía de los tumores epiteliales malignos del ovario. Download Citation on ResearchGate | Cistadenofibroma endometrioide borderline de ovario: un tumor infrecuente | Existen pocos casos publicados de. Corte histológico de tumor borderline de ovário. Coloração hematoxilina-eosina. Aumento de 10x. Presença de múltiplas projeções papilíferas revestidas por.

Author: Sajin Malasida
Country: Namibia
Language: English (Spanish)
Genre: Photos
Published (Last): 17 January 2004
Pages: 354
PDF File Size: 6.47 Mb
ePub File Size: 3.7 Mb
ISBN: 207-9-70726-176-6
Downloads: 95129
Price: Free* [*Free Regsitration Required]
Uploader: Mihn

They are divided into two subtypes: Some authors recommend platinum-based therapy for patients with invasive peritoneal implants because of their worse prognosis. In one series of 28 borderline tumor—related deaths, 2 patients died of radiation-associated complications, 9 of chemotherapy-associated complications, 8 of bowel obstruction, and 8 of invasive carcinoma.

This website also contains tumof copyrighted by 3rd parties.

According to Dietel and Hauptmann, the histology of borderline tumors is characterized by the following features:. The stromal microinvasion is a controversial independent prognostic factor since it appears more frequently bordeerline serous BOT, and is associated with a higher frequency of micropapillary pattern and the appearance of peritoneal implants.

Management of borderline ovarian tumours: a comprehensive review of the literature

Doppler Ultrasonography Preoperative transvaginal color Doppler ultrasonography has been used to assess the possibility of malignancy in ovarian masses.

The FIGO stage classification is considered to be the greatest prognostic factor for recurrence and survival of BOT [ 17 ], as it is in invasive carcinomas, but in contrast to these, bordsrline overall survival rate is greater. Print this section Print the entire contents of Print the entire contents of article. For this reason, there are no current indications for the use of chemotherapy or hormone bordreline even in advanced cases.

Br J Obstet Gynaecol ; The latter has a worse prognosis since the majority are associated with a higher rate of recurrence in invasive form, a greater percentage of bilaterality and presence of invasive implants, and upstaging when performing restaging surgery [ 12710 ]. Many clinicians group stages II-IV together for prognostic consideration. Author information Article notes Copyright gumor License information Disclaimer. Borderline ovarian tumours differ from epithelial ovarian cancer by their low incidence, frequent association with infertility, low association with mutations in BCRA genes, different percentages of the most common histological types, early stage diagnosis, and high survival rate, even when associated with peritoneal involvement.


Biomarkers and Borderilne Cytometry Cancer antigen CA levels are not shown to aid in the diagnosis or follow-up care borderpine patients with borderline tumors.


No destructive stromal invasion – A major component in differentiating malignant from borderline tumors. However, little has been done on borderline ovarian cancer, mostly because of its low incidence and good prognosis. In addition, ovagio in the KRAS gene may be implicated in the origin of mucinous tumours, with their corresponding progression to mucinous carcinoma [ 3 ]. Most of these recurrences are borderline type, so they do not affect global survival rates [ 3471217 ].

Virchows Arch ; Michael H, Roth LM. Morice P, et al.

Haines and Taylor Obstetrical and Gynecological Pathology. Kvario Obstet Gynecol Scand. In addition, there can be no stromal invasion, which is what differentiates them from invasive carcinomas [ 3610 ].

Management of borderline ovarian tumours: a comprehensive review of the literature

It is neither sensitive nor specific enough to be used as a screening tool in the normal populations. Open in a separate window.

Pseudomyxoma peritonei in women: The histological criteria for diagnosis are: This led the authors to suggest that most patients with borderline tumors died with the disease rather than from the disease. Future Fertility Given the excellent prognosis of patients with stage I disease and its occurrence in women of reproductive age, fertility-sparing surgery is of great interest.


Management and prognostic factors The surgical treatment of BOT depends on the age of the patient, their reproductive wishes, the stage at diagnosis, and the presence or absence of borderlinf implants.

Although ultrasonography is useful in identifying the mass, this medium is not currently able to predict the final pathology of the tumor. Although TP 53 positivity and HER2 overexpression in invasive cancer ovatio been associated with a worse prognosis, tmor same gene profile has conferred a survival advantage in borderline tumors.

Am J Surg Pathol ; To date, no randomized data show a benefit. They occur in younger women, which is why one of the objectives in these patients will be the preservation of fertility.

Negava qualquer queixa gastrointestinal. In patients with stage II-IV disease, the prognosis is different; an ofario stage is associated with a worse prognosis and only age at diagnosis and the presence of invasive implants are shown bordrrline influence prognosis.

Birderline R, Scully RE. Preoperatively, borderline tumors are often presumed to be either benign or malignant ovarian masses; however, as with other ovarian masses, staging is performed surgically.

All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. Theoretically, long-term survival would be diminished in patients with non-optimal staging with invasive implants, although the data do not seem to be statistically significant in the literature, probably due to the good overall prognosis of BOT and the low number of cases of each series [ 471014borderlins ].

However, only half of these patients underwent complete staging. Endocrine System Cancers Ovqrio Cancer.